Cost-effectiveness of a smoking cessation program implemented at the time of surgery for lung cancer

Christopher G. Slatore, David H. Au, William Hollingworth

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background: Many patients are active smokers at the time of a diagnosis of surgically resectable lung cancer. Perioperative smoking cessation is associated with improved survival, but the costeffectiveness of a smoking cessation program initiated immediately before surgery is unknown. Methods: We developed a decision analytic Markov model to evaluate the incremental cost-effectiveness of a formal smoking cessation program. The parameter estimates were taken from the available literature. The model included the cost and effectiveness of the smoking cessation program, cost and incidence of perioperative complications, postoperative mortality, and utility measured in quality adjusted life years (QALY). Dollars per QALY and life year were calculated and one-way sensitivity analyses were performed. Results: The cost/QALY and cost/life year were $16,415 and $45,629 at 1 year after surgery and $2609 and $2703 at 5 years, respectively. Most sensitivity analyses showed the 1 year postsurgery cost/QALY estimates were less than $50,000, and all were less than $12,000 at 5 years. Cost-effectiveness estimates were most sensitive to the frequency of perioperative complications and the estimated short-term utility estimates. Conclusion: A smoking cessation program initiated before surgical lung resection is cost-effective at both 1 and 5 years postsurgery. Providers should encourage patients who are still smoking to engage in formal smoking cessation programs.

Original languageEnglish (US)
Pages (from-to)499-504
Number of pages6
JournalJournal of Thoracic Oncology
Volume4
Issue number4
DOIs
StatePublished - Apr 2009
Externally publishedYes

Fingerprint

Smoking Cessation
Cost-Benefit Analysis
Lung Neoplasms
Quality-Adjusted Life Years
Costs and Cost Analysis
Smoking
Lung
Survival
Mortality
Incidence

Keywords

  • Cost-effectiveness
  • Non-small cell lung cancer
  • QALY
  • Smoking cessation program

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Medicine(all)

Cite this

Cost-effectiveness of a smoking cessation program implemented at the time of surgery for lung cancer. / Slatore, Christopher G.; Au, David H.; Hollingworth, William.

In: Journal of Thoracic Oncology, Vol. 4, No. 4, 04.2009, p. 499-504.

Research output: Contribution to journalArticle

@article{325dffea17cd442ea3595c53b4581633,
title = "Cost-effectiveness of a smoking cessation program implemented at the time of surgery for lung cancer",
abstract = "Background: Many patients are active smokers at the time of a diagnosis of surgically resectable lung cancer. Perioperative smoking cessation is associated with improved survival, but the costeffectiveness of a smoking cessation program initiated immediately before surgery is unknown. Methods: We developed a decision analytic Markov model to evaluate the incremental cost-effectiveness of a formal smoking cessation program. The parameter estimates were taken from the available literature. The model included the cost and effectiveness of the smoking cessation program, cost and incidence of perioperative complications, postoperative mortality, and utility measured in quality adjusted life years (QALY). Dollars per QALY and life year were calculated and one-way sensitivity analyses were performed. Results: The cost/QALY and cost/life year were $16,415 and $45,629 at 1 year after surgery and $2609 and $2703 at 5 years, respectively. Most sensitivity analyses showed the 1 year postsurgery cost/QALY estimates were less than $50,000, and all were less than $12,000 at 5 years. Cost-effectiveness estimates were most sensitive to the frequency of perioperative complications and the estimated short-term utility estimates. Conclusion: A smoking cessation program initiated before surgical lung resection is cost-effective at both 1 and 5 years postsurgery. Providers should encourage patients who are still smoking to engage in formal smoking cessation programs.",
keywords = "Cost-effectiveness, Non-small cell lung cancer, QALY, Smoking cessation program",
author = "Slatore, {Christopher G.} and Au, {David H.} and William Hollingworth",
year = "2009",
month = "4",
doi = "10.1097/JTO.0b013e318195e23a",
language = "English (US)",
volume = "4",
pages = "499--504",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "4",

}

TY - JOUR

T1 - Cost-effectiveness of a smoking cessation program implemented at the time of surgery for lung cancer

AU - Slatore, Christopher G.

AU - Au, David H.

AU - Hollingworth, William

PY - 2009/4

Y1 - 2009/4

N2 - Background: Many patients are active smokers at the time of a diagnosis of surgically resectable lung cancer. Perioperative smoking cessation is associated with improved survival, but the costeffectiveness of a smoking cessation program initiated immediately before surgery is unknown. Methods: We developed a decision analytic Markov model to evaluate the incremental cost-effectiveness of a formal smoking cessation program. The parameter estimates were taken from the available literature. The model included the cost and effectiveness of the smoking cessation program, cost and incidence of perioperative complications, postoperative mortality, and utility measured in quality adjusted life years (QALY). Dollars per QALY and life year were calculated and one-way sensitivity analyses were performed. Results: The cost/QALY and cost/life year were $16,415 and $45,629 at 1 year after surgery and $2609 and $2703 at 5 years, respectively. Most sensitivity analyses showed the 1 year postsurgery cost/QALY estimates were less than $50,000, and all were less than $12,000 at 5 years. Cost-effectiveness estimates were most sensitive to the frequency of perioperative complications and the estimated short-term utility estimates. Conclusion: A smoking cessation program initiated before surgical lung resection is cost-effective at both 1 and 5 years postsurgery. Providers should encourage patients who are still smoking to engage in formal smoking cessation programs.

AB - Background: Many patients are active smokers at the time of a diagnosis of surgically resectable lung cancer. Perioperative smoking cessation is associated with improved survival, but the costeffectiveness of a smoking cessation program initiated immediately before surgery is unknown. Methods: We developed a decision analytic Markov model to evaluate the incremental cost-effectiveness of a formal smoking cessation program. The parameter estimates were taken from the available literature. The model included the cost and effectiveness of the smoking cessation program, cost and incidence of perioperative complications, postoperative mortality, and utility measured in quality adjusted life years (QALY). Dollars per QALY and life year were calculated and one-way sensitivity analyses were performed. Results: The cost/QALY and cost/life year were $16,415 and $45,629 at 1 year after surgery and $2609 and $2703 at 5 years, respectively. Most sensitivity analyses showed the 1 year postsurgery cost/QALY estimates were less than $50,000, and all were less than $12,000 at 5 years. Cost-effectiveness estimates were most sensitive to the frequency of perioperative complications and the estimated short-term utility estimates. Conclusion: A smoking cessation program initiated before surgical lung resection is cost-effective at both 1 and 5 years postsurgery. Providers should encourage patients who are still smoking to engage in formal smoking cessation programs.

KW - Cost-effectiveness

KW - Non-small cell lung cancer

KW - QALY

KW - Smoking cessation program

UR - http://www.scopus.com/inward/record.url?scp=67649387273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649387273&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e318195e23a

DO - 10.1097/JTO.0b013e318195e23a

M3 - Article

C2 - 19204575

AN - SCOPUS:67649387273

VL - 4

SP - 499

EP - 504

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 4

ER -